Sinapultide - Windtree Therapeutics

Drug Profile

Sinapultide - Windtree Therapeutics

Alternative Names: Aerosolized KL4 surfactant; AEROSURF; ATI-01; ATI-02; DSC-104; DSC-105; KL-4 lung surfactant; KL4 pulmonary surfactant; KL4 surfactant; Lucinactant; Surfaxin; Surfaxin LS

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Scripps Research Institute
  • Developer Discovery Laboratories; University of Pennsylvania; Windtree Therapeutics
  • Class Amino acids; Peptides; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Neonatal respiratory distress syndrome; Acute lung injury; Adult respiratory distress syndrome; Meconium aspiration syndrome; Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome
  • Preclinical Lung disorders
  • No development reported Acute lung injury; Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Chronic obstructive pulmonary disease; Cystic fibrosis; Reperfusion injury
  • Discontinued Asthma; Meconium aspiration syndrome; Otitis media; Respiratory insufficiency; Rhinitis; Sinusitis

Most Recent Events

  • 14 Nov 2017 Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Inhalation, Aerosol)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease(Combination therapy) in USA (Inhalation, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top